Toni Choueiri, MD· @DrChoueiri · X·· 14 hours agoScore90
Body
Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12.7 months (HR 0.42). A major advance for patients with SCLC! #ESMO26 @oncoalert @myESMO
468 views · 13 likes · 9 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Toni Choueiri, MD · x.com